[go: up one dir, main page]

MX2017013074A - Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer. - Google Patents

Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.

Info

Publication number
MX2017013074A
MX2017013074A MX2017013074A MX2017013074A MX2017013074A MX 2017013074 A MX2017013074 A MX 2017013074A MX 2017013074 A MX2017013074 A MX 2017013074A MX 2017013074 A MX2017013074 A MX 2017013074A MX 2017013074 A MX2017013074 A MX 2017013074A
Authority
MX
Mexico
Prior art keywords
cancer
methods
prediction
compositions
therapeutic effectiveness
Prior art date
Application number
MX2017013074A
Other languages
English (en)
Other versions
MX387857B (es
Inventor
Sahin Ugur
Türeci Özlem
Maurus Daniel
Original Assignee
Ganymed Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Gmbh filed Critical Ganymed Pharmaceuticals Gmbh
Publication of MX2017013074A publication Critical patent/MX2017013074A/es
Publication of MX387857B publication Critical patent/MX387857B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere en general a métodos y composiciones para la predicción de la eficacia terapéutica de tratamientos contra el cáncer y la prognosis de cáncer. La invención describe marcadores que se asocian con resultados favorables y desfavorables, respectivamente, en ciertos tratamientos contra el cáncer y son útiles como marcadores de pronóstico para el cáncer. Los métodos que implican estos marcadores se describen para predecir el beneficio de la terapia de cáncer y pronosticar el resultado clínico para los pacientes con cáncer.
MX2017013074A 2015-04-15 2016-04-13 Métodos y composiciones para predicción de eficacia terapéutica de tratamientos contra el cáncer y prognosis del cáncer. MX387857B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2015/058212 WO2016165765A1 (en) 2015-04-15 2015-04-15 Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
PCT/EP2016/058061 WO2016166124A1 (en) 2015-04-15 2016-04-13 Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis

Publications (2)

Publication Number Publication Date
MX2017013074A true MX2017013074A (es) 2018-03-15
MX387857B MX387857B (es) 2025-03-19

Family

ID=52829110

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017013074A MX387857B (es) 2015-04-15 2016-04-13 Métodos y composiciones para predicción de eficacia terapéutica de tratamientos contra el cáncer y prognosis del cáncer.
MX2021013938A MX2021013938A (es) 2015-04-15 2017-10-11 Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013938A MX2021013938A (es) 2015-04-15 2017-10-11 Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.

Country Status (16)

Country Link
US (4) US10927413B2 (es)
EP (1) EP3283644B1 (es)
JP (4) JP6976855B2 (es)
KR (3) KR102409933B1 (es)
CN (2) CN119177284A (es)
AU (1) AU2016249784B2 (es)
CA (1) CA2982390A1 (es)
ES (1) ES2787708T3 (es)
HK (1) HK1246829A1 (es)
IL (3) IL296503B2 (es)
MA (1) MA42974A (es)
MX (2) MX387857B (es)
SG (1) SG11201708270YA (es)
UA (1) UA128575C2 (es)
WO (2) WO2016165765A1 (es)
ZA (1) ZA201705936B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016165765A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN108330180A (zh) * 2017-10-25 2018-07-27 广州和康医疗技术有限公司 一种对fcgr3a位点进行基因型检测的方法及试剂盒
CN111630186A (zh) * 2018-01-23 2020-09-04 北京艾克伦医疗科技有限公司 鉴定肺癌状态的方法和试剂盒
BR112020015479A2 (pt) 2018-03-08 2020-12-08 Phanes Therapeutics, Inc. Anticorpos anticlaudina 18.2 e usos dos mesmos
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
US12415853B2 (en) 2019-05-16 2025-09-16 Qilu Pharmaceutical Co., Ltd. Antibody against claudin 18A2 and use thereof
CN112133369B (zh) * 2020-08-26 2023-09-22 吴安华 基于活性氧评估肿瘤患者预后性的系统以及药物敏感性评价与改善方法
KR102809807B1 (ko) * 2021-12-21 2025-05-16 한림대학교 산학협력단 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
CN114783609B (zh) * 2022-05-11 2025-07-15 深圳市人民医院 一种基于pus家族基因的肝细胞癌预后评分系统及其应用
CN120344654A (zh) 2022-12-29 2025-07-18 安斯泰来制药有限公司 改造的自然杀伤细胞和相关方法
WO2024211459A1 (en) * 2023-04-04 2024-10-10 Zai Lab (Shanghai) Co., Ltd Use of anti-claudin antibody for cancer treatment based on certain biomarkers
CN116926198A (zh) * 2023-09-15 2023-10-24 臻和(北京)生物科技有限公司 检测胃癌组织Claudin18.2蛋白阳性的方法、装置、设备和存储介质
CN117701719B (zh) * 2024-02-04 2024-05-31 北京肿瘤医院(北京大学肿瘤医院) 肿瘤靶向cldn18.2治疗耐药标志物及其应用
CN120843703A (zh) * 2025-07-24 2025-10-28 上海市生物医药技术研究院 一种利用癌组织的特定微生物预测乳腺癌原位复发的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2502552C (en) 2002-10-17 2019-02-12 Genmab A/S Human monoclonal antibodies against cd20
CA2797182C (en) * 2010-04-21 2019-02-12 Ventirx Pharmaceuticals, Inc. Methods of enhancing antibody-dependent cellular cytotoxicity
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2016165765A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis

Also Published As

Publication number Publication date
EP3283644A1 (en) 2018-02-21
JP2025010323A (ja) 2025-01-20
KR20220086708A (ko) 2022-06-23
JP2022023226A (ja) 2022-02-07
KR102722572B1 (ko) 2024-10-29
ES2787708T3 (es) 2020-10-16
IL296503A (en) 2022-11-01
JP2023040269A (ja) 2023-03-22
US20180073077A1 (en) 2018-03-15
CN107873061B (zh) 2022-09-13
IL254086B2 (en) 2023-04-01
IL254086A0 (en) 2017-10-31
JP2018512146A (ja) 2018-05-17
US12188097B2 (en) 2025-01-07
CN119177284A (zh) 2024-12-24
WO2016166124A1 (en) 2016-10-20
US20250092469A1 (en) 2025-03-20
US10927413B2 (en) 2021-02-23
NZ736368A (en) 2021-09-24
JP7581391B2 (ja) 2024-11-12
AU2016249784A1 (en) 2017-11-02
KR20170138431A (ko) 2017-12-15
US20240110247A1 (en) 2024-04-04
IL296503B1 (en) 2023-10-01
RU2017139489A (ru) 2019-05-15
BR112017018775A2 (pt) 2018-04-17
ZA201705936B (en) 2019-06-26
US11732308B2 (en) 2023-08-22
SG11201708270YA (en) 2017-11-29
HK1246829A1 (zh) 2018-09-14
JP7217327B2 (ja) 2023-02-02
JP6976855B2 (ja) 2021-12-08
IL254086B (en) 2022-12-01
KR20240155985A (ko) 2024-10-29
IL305880A (en) 2023-11-01
MX387857B (es) 2025-03-19
UA128575C2 (uk) 2024-08-21
US20210324472A1 (en) 2021-10-21
MX2021013938A (es) 2022-01-04
WO2016165765A1 (en) 2016-10-20
AU2016249784B2 (en) 2021-03-11
MA42974A (fr) 2018-08-22
CA2982390A1 (en) 2016-10-20
KR102409933B1 (ko) 2022-06-17
EP3283644B1 (en) 2020-04-01
CN107873061A (zh) 2018-04-03
RU2017139489A3 (es) 2019-11-18
IL296503B2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
MX2017013074A (es) Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.
CL2018002759A1 (es) Compuestos de pirrolotriazina como inhibidores de tam.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
CL2017000521A1 (es) Inhibidores de desmetilasa-1 específica a lisina
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
ECSP17020812A (es) Agentes de unión a cd123 y usos de estos
CR20170014A (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MX394676B (es) Métodos para tratar el cáncer.
MX2015010724A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX384490B (es) Agentes que inducen apoptosis para el tratamiento de cancer y enfermedades inmunitarias y autoinmunitarias.
BR112017012142A2 (pt) método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
BR112014024017A8 (pt) Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
BR112017002526A2 (pt) terapia adjuvante com 25-hidroxivitamina d
CO2017000359A2 (es) Compuestos derivados de piridina sustituidos como inhibidores de histonas desmetilasa
CL2017001960A1 (es) Métodos de tratamiento de enfermedades inflamatorias
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
DOP2019000019A (es) Metodos para tratar el cancer de prostata
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario